EP Patent

EP4719374A1 — Treatment regimens for early idiopathic parkinson's disease

Assigned to Bial Portela and Cia SA · Expires 2026-04-08 · 0y expired

What this patent protects

Opicapone for use as adjunctive therapy to preparations of levodopa and a DOPA decarboxylase inhibitor (DDCI) in the treatment of Parkinson's disease; characterised in that a patient with Parkinson's disease is treatable with preparations of levodopa and a DDCI without clinically…

USPTO Abstract

Opicapone for use as adjunctive therapy to preparations of levodopa and a DOPA decarboxylase inhibitor (DDCI) in the treatment of Parkinson's disease; characterised in that a patient with Parkinson's disease is treatable with preparations of levodopa and a DDCI without clinically diagnosed motor complications.

Drugs covered by this patent

Patent Metadata

Patent number: EP4719374A1
Jurisdiction: EP
Classification: —
Expires: 2026-04-08
Drug substance claim: No
Drug product claim: No
Assignee: Bial Portela and Cia SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.